Company intelligence / Profile preview

Anteris Technologies

Brisbane, Australia

Ownership: Public · AVR
Development stage: Phase 1

Overview

Anteris Technologies has developed the ADAPT® anti-calcification tissue, clinically proven to be calcium-free for up to ten years and used in over 55,000 patients as a cardiac and vascular patch. Their lead product, the DurAVR® Transcatheter Heart Valve (THV), uses this biomimetic tissue platform to restore healthy blood flow patterns in patients with aortic stenosis. The company positions its TAVR solution as superior for younger and more active patients due to its durability and physiological performance.

Therapeutic areas: Cardiovascular
Modalities: DeviceBiologic
Industry: Implantable Medical Devices

Drug pipeline

2 assets

DurAVR THV

Phase 1

Indications: Aortic stenosis

1 more asset in the full pipeline.

Request access →

Financials

Market cap: $838.1M
Total revenue: $1M
Enterprise value: $584.1M

Beyond the preview

Go deeper on Anteris Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anteris Technologies.

Explore the full profile